

Journal Pre-proof

A-BRAVE trial: a Phase 3 randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients

P.F. Conte, M.V. Dieci, G. Bisagni, P. Schmid, A. Zambelli, F. Piacentini, M. De Laurentiis, A.G. Favaretto, S. Tamberi, G.V. Bianchi, C. Zamagni, S. Cinieri, D.C. Corsi, L. Del Mastro, A. Ferro, A. Gennari, M. Mion, A. Musolino, L. Nicolé, P. Del Bianco, G.L. De Salvo, V. Guarneri

PII: S0923-7534(25)00925-1

DOI: <https://doi.org/10.1016/j.annonc.2025.08.005>


Reference: ANNONC 1882

To appear in: *Annals of Oncology*

Received Date: 13 May 2025

Revised Date: 25 July 2025

Accepted Date: 18 August 2025




Please cite this article as: Conte PF, Dieci MV, Bisagni G, Schmid P, Zambelli A, Piacentini F, De Laurentiis M, Favaretto AG, Tamberi S, Bianchi GV, Zamagni C, Cinieri S, Corsi DC, Del Mastro L, Ferro A, Gennari A, Mion M, Musolino A, Nicolé L, Del Bianco P, De Salvo GL, Guarneri V, A-BRAVE trial: a Phase 3 randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients, *Annals of Oncology* (2025), doi: <https://doi.org/10.1016/j.annonc.2025.08.005>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.

A-BRAVE:
Adjuvant avelumab treatment for 1-year versus observation in high-risk, early TNBC following standard surgery and neoadjuvant/adjuvant chemotherapy



A-BRAVE trial: a Phase 3 randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients

P.F. Conte^{1*}, M.V. Dieci^{1,2*}, G. Bisagni³, P. Schmid⁴, A. Zambelli^{5,6}, F. Piacentini^{7,8}, M. De Laurentiis⁹, A.G. Favaretto¹⁰, S. Tamberi¹¹, G.V. Bianchi¹², C. Zamagni¹³, S. Cinieri¹⁴, D.C. Corsi¹⁵, L. Del Mastro^{16,17}, A. Ferro¹⁸, A. Gennari¹⁹, M. Mion²⁰, A. Musolino^{21,22}, L. Nicolé²³, P. Del Bianco²⁴, G.L. De Salvo²⁴, V. Guarneri^{1,2†}

¹Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy

²Oncology 2, Veneto Institute of Oncology IOV IRCCS, Padova, Italy

³Department of Oncology and Advanced Technologies, Azienda USL-IRCCS, Reggio Emilia, Italy

⁴Cancer Institute, Queen Mary University of London, London, United Kingdom

⁵ASST Papa Giovanni XXIII, Bergamo, Italy

⁶School of Medicine and Surgery, Bicocca University, Milan, Italy

⁷Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena, Modena, Italy

⁸Azienda Ospedaliero-Universitaria di Modena, Modena, Italy

⁹Istituto Nazionale Tumori Napoli IRCCS "Fondazione Pascale", Napoli, Italy

¹⁰Azienda ULSS 2 Marca Trevigiana, Treviso, Italy

¹¹Oncology Unit, Santa Maria delle Croci hospital, Ravenna, Italy

¹²Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, Italy

¹³IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

¹⁴Department of Medical Oncology, Perrino Hospital, ASL Brindisi, Brindisi, Italy

¹⁵Ospedale Isola Tiberina, Gemelli Isola Rome, Italy

¹⁶IRCCS Ospedale Policlinico San Martino, Genova, Italy

¹⁷Università degli Studi di Genova, Genova, Italy

¹⁸Santa Chiara Hospital, Trento, Italy

¹⁹Università del Piemonte Orientale, Dipartimento di Medicina Traslazionale - DIMET, Novara, Italy

²⁰AULSS6 Camposampiero, Camposampiero, Italy

²¹Medical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy

²²Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy

²³Pathology, Angelo Hospital, Mestre, Italy

²⁴Clinical Research Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy

*These authors contributed equally as first authors.

†Corresponding author: Prof. Valentina Guarneri

Mailing address: Department of Surgery, Oncology and Gastroenterology - University of Padova

Division of Medical Oncology 2 - Veneto Institute of Oncology IOV-IRCCS Via Gattamelata 64, 35128, Padova, Italy

Tel: +390498215291

Fax: +390498215932

Email: valentina.guarneri@unipd.it

Word count: 3570 (4470 including figures and tables)

Tables and Figures: 6

Abstract

Background: The A-BRAVE trial evaluated the efficacy of avelumab, an anti PD-L1 antibody, as adjuvant treatment for patients with early triple-negative breast cancer (TNBC) at high-risk.

Patients and Methods: A-BRAVE is a Phase III study that randomized patients with high-risk early TNBC to 1-year avelumab vs observation, after completion of standard surgery and neoadjuvant/adjuvant chemotherapy. High-risk was defined as either: 1) \geq pN2/any pT, pN1/pT2, or pN0/pT3 after primary surgery (Stratum A); or 2) invasive residual disease (breast and/or nodes) after neoadjuvant chemotherapy (Stratum B). Co-primary endpoints were disease-free survival (DFS) in the intention-to-treat (ITT) and Stratum B populations (). Secondary endpoints were overall survival (OS) and DFS in PD-L1-positive patients. PD-L1 was evaluated in treatment-naïve tumor samples by immunohistochemistry (73-10 RUO assay, Agilent Technologies) and digital pathology.

Results: From June 2016 to October 2020, 466 patients were randomized: 383 entered Stratum B (82%) and 83 entered Stratum A (18%). At a median follow of 52.1 months, avelumab did not significantly improve DFS in the ITT population (HR 0.81, 95% CI 0.61–1.09, $p=0.172$; 3-year DFS estimates were 68.3% for avelumab versus 63.2%), or in Stratum B (HR 0.80, 95% CI 0.58–1.10, $p=0.170$; 3-year DFS estimates were 66.9% for avelumab versus 60.7%). In a descriptive analysis, avelumab reduced the hazard of OS events: HR 0.66, 95% CI: 0.45–0.97. The 3-year OS estimates for avelumab and control arm were 84.8% (95% CI: 79.5–88.8) and 76.3% (95% CI: 70.1–81.3), respectively. PD-L1 status resulted prognostic but not predictive for avelumab benefit in terms of DFS (test for interaction $p=0.155$).

Conclusions: For patients with TNBC at high risk of relapse who complete standard treatment with surgery and neoadjuvant/adjuvant chemotherapy, 1 year of adjuvant avelumab versus observation did not improve DFS. However, a descriptive analysis suggests a potential favorable impact on OS.

ClinicalTrials.gov identifier: [NCT02926196](https://clinicaltrials.gov/ct2/show/study/NCT02926196)

Key words: Breast cancer, clinical trial, immunotherapy, triple-negative breast cancer, PD-L1

Highlights

- A-BRAVE is a Phase III study of 1-year avelumab versus observation after standard treatment in high-risk TNBC.
- Avelumab as adjuvant therapy versus observation did not improve DFS in high-risk early TNBC patients
- OS analysis suggests a potential favorable impact of avelumab versus observation.
- PD-L1 status was not predictive for avelumab efficacy.

INTRODUCTION

Neoadjuvant systemic therapy is recommended for patients with triple-negative breast cancer (TNBC) diagnosed with a tumor larger than 1 cm and/or axillary lymph node involvement¹, which facilitates surgical de-escalation and the stratification of patients by pathological response, to tailor adjuvant treatment¹². Patients who achieve a pathological complete response (pCR) experience a very favorable long-term survival, while those with invasive residual disease (iRD) are exposed to a higher risk of relapse³. Thus, the neoadjuvant platform provides an ideal framework for advancing personalized treatment, by attempting to maximize the pCR rate through the incorporation of new drugs in the pre-operative phase, and at lowering the risk of relapse in patients with iRD by escalating adjuvant treatment⁴; a trial design strategy that is endorsed by the US Food and Drug Administration (FDA)⁵. Notwithstanding, some patients with early TNBC still undergo primary surgery followed by adjuvant chemotherapy, based on clinical staging \leq cT1cN0, and/or other individual or clinical considerations. For these patients, definitive pathological staging is a major prognostic factor⁶.

TNBC is the most immunogenic breast cancer subtype because of its genetic instability and high mutational burden⁷. Immune checkpoint inhibitors (ICIs) combined with chemotherapy have improved the prognosis of patients with advanced TNBC^{8,9}. Moreover, nowadays neoadjuvant chemotherapy combined with pembrolizumab is standard for T>2cm and/or positive axillary lymph node involvement¹⁰. Avelumab is a fully human anti-programmed death-ligand 1 (PD-L1) antibody that showed clinical activity and an acceptable safety profile in the metastatic breast cancer cohort (including TNBC) of the Phase 1b JAVELIN Solid Tumor trial¹¹.

A-BRAVE is an investigator-driven trial that was designed in 2015 before any efficacy data of ICIs in early TNBC were available, to investigate the efficacy of adjuvant avelumab in patients with early TNBC considered at high-risk of relapse after the conclusion of treatment

with curative intent, including chemotherapy and surgery. Here we report primary, secondary, and exploratory efficacy endpoints.

METHODS

Trial oversight

The A-BRAVE trial (EUDRACT 2016-000189-45; NCT02926196) was an investigator-initiated, multicenter, unblinded, randomized trial conducted in 60 Italian and 7 UK hospitals (**Supplementary Table S3**). This trial was developed and sponsored by the Department of Surgery, Oncology and Gastroenterology of the University of Padova, Italy. The healthcare business of Merck KGaA, Darmstadt, Germany supported the trial with an unrestricted grant and supply of avelumab, but had no role in the design or conduct of the trial and was not involved in data collection or analysis, in the writing of the manuscript, or in the decision to submit it for publication. The trial protocol and all amendments were approved by the appropriate ethics body at each participating institution (**Supplementary Information**). The trial was performed in accordance with the standards of Good Clinical Practice. The authors assume responsibility for the accuracy and completeness of the data and analyses, as well as for the fidelity of the trial and this report to the protocol.

Patients

Patients were eligible for enrollment if they were aged ≥ 18 years, had hormone receptor negative (estrogen receptor [ER] $< 10\%$ and progesterone receptor [PgR] $< 10\%$) and human epidermal growth factor receptor 2 (HER2) negative (immunohistochemistry [IHC] 0/1+ or 2+ in situ hybridization non-amplified) non-metastatic breast cancer as defined by local laboratory, and had received treatment with curative intent, including surgery and chemotherapy with anthracyclines and taxanes. Patients should have met the following

protocol criteria for the definition of high-risk: any pT \geq pN2, pT2/pN1, or pT3/pN0 according to the local pathology examination of samples obtained with primary surgery (Stratum A, adjuvant); iRD in the breast and/or lymph nodes as determined by local pathology examination of the surgical specimen obtained after neoadjuvant chemotherapy (Stratum B, post-neoadjuvant; ypT1micN0, ypT1micN0i+, ypT0N0i+ excluded). In Stratum B, no more than 6 months of adjuvant chemotherapy after neoadjuvant treatment and surgery was allowed according to a protocol amendment (April 2018). A complete list of the inclusion and exclusion criteria are provided in the trial protocol (**Supplementary Information**).

Trial procedures

Participants were randomly assigned (web-based) in a 1:1 ratio to either avelumab monotherapy administered as intravenous infusion at the dose of 10mg/kg every 2 weeks for 52 weeks (avelumab arm) or to observation (control arm). Randomization was stratified by Stratum A (adjuvant) and Stratum B (post-neoadjuvant) and had to occur \leq 10 weeks from the end of adjuvant chemotherapy or the date of definitive surgery (Stratum B in the absence of post-surgical cytotoxic treatment). Treatment administration had to start within 7 days from randomization. Radiotherapy was allowed concomitantly to avelumab administration. Adjuvant endocrine therapy was allowed at investigator's discretion for patients whose tumor expressed low levels of hormone receptors (1% to 9%). Visits for assessment of disease recurrence were scheduled every 4 months from the first 2 years, every 6 months from year 3 to 5, and once a year thereafter in both arms. In the avelumab arm, adverse events were monitored throughout the trial and for 90 days after the last avelumab administration. For patients randomized to the control arm, safety was assessed during the first 12 months at the scheduled visits and by additional monthly phone calls.

Outcomes

Efficacy was evaluated in the ITT population including all randomized patients. Initially the two co-primary endpoints were: i) DFS of patients randomized to avelumab compared to control (whole ITT); ii) DFS of patients randomized to avelumab compared to control in the PD-L1 positive population. After amendment in January 2020, the two co-primary endpoints were modified as follows: i) DFS of patients randomized to avelumab compared to control (whole ITT); ii) DFS of patients randomized to avelumab compared to control in Stratum B. DFS in the PD-L1 positive population was maintained as a secondary endpoint. The rationale for withdrawing DFS in PD-L1 positive patients as a co-primary endpoint was based on the emerging KEYNOTE-522 trial data, that did not demonstrate any predictive role of PD-L1 status relative to the efficacy of neoadjuvant pembrolizumab combined with chemotherapy. The decision to introduce DFS in Stratum B as a co-primary endpoint was taken, considering the increasing interest in escalating adjuvant therapy in case of iRD following the success of recent clinical trials^{2,12}, that was also endorsed by the FDA⁵.

Another secondary efficacy endpoint was OS in the whole ITT. Distant DFS (DDFS) was a post-hoc exploratory analysis.

DFS was defined as the time interval between randomization and any of the following events, whichever first: local, regional, and distant recurrence; second primary invasive breast cancer; other second primary invasive cancer; death. OS was calculated from randomization to death from any cause. DDFS was defined as the time interval from randomization to distant recurrence; second primary invasive cancer (non-breast); death. For all endpoints, patients without event were censored at the last follow-up date.

Safety (secondary endpoint) was assessed including all patients who received at least one dose of avelumab, and all patients randomized to control. Toxicities were graded using the National Cancer Institute – Common Terminology Criteria for Adverse Events v.4.03.

1 **Statistical analysis**

2 The study design fixed a 1-sided significance level at 2.0% for the overall analysis. For the
3 subgroup analysis, the significance level was adjusted using the Spiessens and Debois
4 method to control the Family-Wise Error Rate at 2.5% (1-sided)¹³.

5 In TNBC patients meeting the A-BRAVE criteria and randomized to the control arm, the 3-
6 year DFS rate was expected to be 60% (with similar estimates for both Stratum A and B)^{3,6}.
7 An improvement to 73.6% in the 3-year DFS rate was the target effect for the entire ITT
8 population. This corresponds to an expected hazard ratio (HR) of 0.6 for the avelumab arm
9 versus the control arm, assuming an exponential distribution.

10 Under the proportional hazards assumption, 172 DFS events were required to detect an
11 expected HR of 0.60 with 90% power using a 1-sided log-rank test at a 2.0% significance
12 level. Assuming uniform enrollment over a 4-year period, a follow-up of at least 2 years after
13 the last participant was randomized, and 6% lost to follow-up, it was estimated that 474
14 participants (237 in each group) would need to be randomized.

15 For the second co-primary endpoint, assuming 80% of the total DFS events occur in Stratum
16 B, the power to detect a HR of 0.60 in this subgroup was 79% at an allocated alpha of 1.43%.
17 If the hypothesis for the first co-primary endpoint was rejected at the 2.0% level, the
18 hypothesis for Stratum B would be tested at an alpha of 2.5% with 85% power.

19 Kaplan-Meier estimates were provided with 95% confidence interval computed using the
20 Greenwood formula. HRs and 95% confidence intervals (CI) were estimated using a Cox
21 proportional hazards model, stratified by randomization factor.

22 Results for the secondary and exploratory endpoints are reported as descriptive analyses,
23 without any formal statistical tests for comparison between avelumab and observation. The

interaction p-values for testing the heterogeneity of the treatment effect within subgroups were assessed using Cox proportional hazards models.

PD-L1

DFS in PD-L1 positive population was a secondary endpoint. As additional exploratory analyses we investigated the prognostic role of PD-L1 for DFS, DDFS and OS, as well as the effect of avelumab on DDFS and OS according to PD-L1 status. PD-L1 was evaluated by IHC (73-10 RUO assay, Agilent Technologies) on treatment-naïve formalin-fixed paraffin-embedded tumor samples (surgical samples for Stratum A, tumor core-biopsies obtained before the start of neoadjuvant chemotherapy for Stratum B). The percentage of positively stained stromal cells out of the total number of stromal cells was calculated by a digital pathology workflow and the cut-off for PD-L1 positive status was set at $\geq 21\%$ ¹⁴. Detailed methods are available in the **Supplementary methods**.

RESULTS

Patients

Between June 2016 and October 2020, a total of 514 patients from 67 centers were screened and 477 randomized: 238 to avelumab and 239 to observation (**Fig. 1**). After randomization, ten patients withdrew consent and one was not eligible, leaving 466 patients in the ITT population evaluable for efficacy analysis. Baseline demographics and clinical characteristics were balanced between the two arms (**Table 1**). The majority of the patients (82%) entered Stratum B (post-neoadjuvant). There was a significant imbalance in carboplatin exposure between arms (35.0% avelumab; 25.5% observation, $p=0.028$). Only

23% of patients in Stratum B received adjuvant capecitabine, without significant difference between arms ($p=0.136$).

Efficacy

The target of 172 patients with at least one DFS event was reached in February 2024 (data cutoff for this analysis: May 2024). At a median follow-up of 52.1 months (95% CI: 49.8–53.8), 81 DFS events were reported in the avelumab arm (34.5%) and 91 (39.4%) in the control arm. Among all DFS events, the most frequent was distant recurrence (accounting for 59.3% events in the avelumab arm and 63.7% in the control arm), followed by locoregional recurrence (32.1% and 23.1%), second primary invasive breast cancer (1.2% and 2.2%), non-breast primary invasive cancer (3.7% and 6.6%), and death (1.2% and 4.4%). Avelumab did not significantly improve DFS as compared to control in the ITT population: HR 0.81, 95% CI: 0.61–1.09; $p=0.172$ (**Fig. 2a**). The 3-Years DFS estimates for avelumab and control arm were 68.3% (95% CI: 61.9–73.8) and 63.2% (95% CI: 56.5–69.0), respectively.

Similarly, avelumab did not significantly improve DFS in stratum B: HR 0.80, 95% CI 0.58–1.10, $p=0.172$ (**Fig. 2b**). The 3-Year DFS estimates for avelumab and control arm in Stratum B were 66.9% (95% CI: 59.8–73.1) and 60.7% (95% CI: 53.3–67.3), respectively.

A total of 108 patients died (94.4% breast cancer-related deaths; **Supplementary Table S1**): 46 in the avelumab arm (19.6%) and 62 (26.8%) in the control arm. According to a descriptive analysis of the secondary endpoint OS, avelumab was associated with a reduction in the hazard of death in the whole ITT: HR 0.66, 95% CI: 0.45–0.97 (**Fig. 3a**). The 3-Year OS estimates in the avelumab and control arms were 84.8% (95% CI: 79.5–88.8) and 76.3% (95% CI: 70.1–81.3), respectively.

1 In order to investigate the reasons for a larger effect of avelumab in terms of OS as
 2 compared to DFS, and considering the slight imbalances in the type of DFS events between
 3 the two arms, a *post hoc* exploratory analysis of DDFS was performed. Sixty-six DDFS
 4 events (28.1%) were reported in the avelumab group and 85 (36.8%) in the control group
 5 (**Fig. 3b**). Among all DDFS events, the most frequent was distant recurrence (81.8% of
 6 events in the avelumab arm and 84.7% in the control arm), followed by death (3.0% and
 7 3.5%), and second primary invasive non-breast cancer (2.1% and 2.2%). In a descriptive
 8 analysis of DDFS, avelumab was associated to a reduction of hazard of events: HR: 0.70,
 9 95% CI: 0.50–0.96. The 3-Year DDFS estimates in the avelumab and control arms were
 10 75.4% (95% CI: 69.3–80.4) and 67.9% (95% CI: 61.4–73.5), respectively.

11 PD-L1 status was available for 407 patients. Patients with PD-L1-positive tumors
 12 experienced a better DFS compared to those with PD-L1-negative tumors (HR: 0.45, 95%
 13 CI 0.26–0.78, $p=0.003$). The HR for DFS comparing avelumab vs control was 1.72 (95% CI
 14 0.58–5.12) in the PD-L1-positive group and 0.76 (95% CI 0.54, 1.08) in the PD-L1-negative
 15 group; test for interaction was $p=0.155$ (**Figure 5**). The test for interaction with PD-L1 1%
 16 increments and treatment arm was $p=0.283$.

17 Exploratory subgroup analyses are shown in **Fig. 4**, **Supplementary Fig. S1**,
 18 **Supplementary Fig. S2**. Additional exploratory analyses, testing other survival endpoints
 19 and alternative cut-offs are available as **Supplementary Figure S3** and **Table S2**.

20

21 **Treatment exposure and safety**

22 Most of the patients who started avelumab were able to complete the planned 52 weeks of
 23 treatment ($n=168$, 72.1%). Eighty-two patients (49%) received all the planned 26 courses
 24 without any delays or temporary interruptions, and 80 patients (47%) received 20 or more
 25 courses. Among patients who prematurely discontinued treatment ($n=65$, 27.9%), reasons

were: disease recurrence (n=33, 50.8%), adverse event (n=20, 30.8%), and patient decision or other (n=12, 18.5%).

The most frequent immune-related adverse event (irAE) with avelumab was thyroid dysfunction: hypothyroidism in 31 patients (13.2%) and hyperthyroidism in 11 patients (4.7%), all grade 1 or 2. Very few patients had a grade 3 immune-related toxicity: transaminase, lipase, amylase increase (three patients each), and colitis (one patient). A summary of irAEs is available in **Supplementary Table S3**.

DISCUSSION

The Phase 3 A-BRAVE trial did not meet its primary endpoint: the HR of 0.81 for DFS with avelumab versus control for patients with TNBC at high-risk of relapse was not statistically significant, with consistent results in the ITT population and those patients with iRD after neoadjuvant chemotherapy (co-primary endpoints). The descriptive analysis of the secondary endpoint OS suggested an improvement with avelumab versus control (HR 0.66; 95% CI: 0.45–0.97). Similarly, a descriptive analysis of post-hoc DDFS indicated a reduction in risk with avelumab (HR 0.70; 95% CI: 0.50–0.96).

Based on a consistent biological rationale and data in advanced disease, ICIs have been extensively investigated for non-metastatic TNBC. Most of the randomized trials so far tested the addition of an ICI to neoadjuvant chemotherapy^{10,15–18}. In some trials, the ICI was continued after surgery^{10,16}. A significant increase in pCR rate was reported by the majority of the studies, but, most importantly, survival outcomes were positively affected by ICIs to a larger extent than pCR^{19–21}. Based on these results, neoadjuvant chemotherapy plus pembrolizumab, with pembrolizumab continued after surgery independently from the pathological response, is now standard of care in many countries. Conversely, the ALEXANDRA trial — where atezolizumab was started concomitantly to adjuvant

chemotherapy and continued for 1 year in patients undergoing primary surgery — was closed for futility at the planned interim analysis²². These data also reinforced the thesis according to which ICIs induce an anti-tumor immune response most effectively when macroscopic disease is present (neoadjuvant) rather than in the eventual presence of micrometastatic disease (adjuvant)²³. Accordingly, preclinical evidence in murine models and clinical evidence in other cancer diseases support a more pronounced activity of ICIs with neoadjuvant administration^{24,25}. Therefore, the main question is how to reconcile and contextualize the results of the A-BRAVE adjuvant trial in this scientific and clinical scenario.

A-BRAVE addressed a different question compared to previous trials in TNBC: how efficacious is adjuvant treatment with an ICI in patients selected for being at high-risk of relapse? The rationale behind this approach is dual: escalate treatment only for those patients who may really need it, and improve tolerability by administering an ICI as a single agent, in the attempt to maximize the benefit/risk ratio of incorporating an ICI in the curative setting for TNBC.

A-BRAVE is formally a negative trial, as the dual co-primary endpoints of DFS were not met. However, the signal for improvement in both OS and DDFS stimulates discussion. Post-hoc exploratory DDFS analysis in this trial must be interpreted with caution and can only be considered as hypothesis generating. However, it is widely recognized that DDFS rather than DFS is a better surrogate for OS^{26,27}. At present there are no conclusive explanations for why the magnitude of difference in OS for avelumab versus control was apparently larger than the difference observed for DFS. Patients with TNBC may carry germline *BRCA1/2* or *PALB2* mutations that determine a significant risk of second tumors, which can be curable and have an impact on DFS without affecting OS and DDFS. In our study, 11% of patients had a documented germline *BRCA1/2* mutation, *PALB2* status was unknown.

1 More than 80% of patients in the A-BRAVE trial met the criteria for Stratum B and did not
2 achieve a pCR after neoadjuvant chemotherapy, while a minority of patients were enrolled
3 in Stratum A. The efficacy of avelumab did not differ by Stratum A or B, however the sample
4 size in the former is limited, making the results of A-BRAVE particularly relevant for patients
5 with iRD after neoadjuvant chemotherapy, while not excluding an effect in Stratum A. In
6 addition, caution is needed when applying these results to patients treated with
7 contemporary chemotherapy regimens (e.g., neoadjuvant carboplatin, post-neoadjuvant
8 capecitabine). In our study, capecitabine was used in only 23% of Stratum B patients, and
9 carboplatin use was inconsistent and imbalanced between arms. Therefore, we cannot
10 confirm that avelumab results would be reproducible in this context. Ongoing studies (e.g.,
11 SWOG S1418) will help clarify the role of ICIs in this setting.

12 Although neoadjuvant pembrolizumab (continued as adjuvant) combined with
13 chemotherapy is standard for stage II–III TNBC, safety is of concern in a curative setting
14 considering the risk of potentially life-threatening and life-long toxicities. In the KEYNOTE-
15 522 trial, the rate of grade ≥ 3 irAEs with pembrolizumab was 12.9% (including four toxic
16 deaths), with most of the events occurring in the neoadjuvant phase¹⁰. With the KEYNOTE-
17 522 regimen applied in the real-world setting, up to 32% of grade ≥ 3 irAEs have been
18 reported²⁸. The low incidence of grade ≥ 3 irAEs with avelumab in the A-BRAVE trial
19 suggests a favorable tolerability profile with an ICI administered as a single agent.

20 As the A-BRAVE trial failed to meet its primary endpoint, the results will not have any direct
21 impact on clinical practice. However, the observed signal suggesting a potential favorable
22 impact of adjuvant avelumab on DDFS and OS, if confirmed by other trials (e.g., SWOG
23 S1418) might, in the future, open the field to personalized algorithms in selected patients.
24 Moreover, it is worth mentioning that the A-BRAVE trial allowed the inclusion of patients in

Stratum B with initial cT1cN0 tumor stage, whereas patients with clinical stage I were excluded from KEYNOTE-522 and do not currently have access to pembrolizumab.

Differences in the patient population between the A-BRAVE and ALEXANDRA trials may explain discrepant results. A-BRAVE included patients at worse prognosis (as clearly recapitulated by survival outcomes in the control arms of both trials). This is true also when focusing only on Stratum A, including 50% of patients with stage III (compared to 15% of patients in the ALEXANDRA trial)²². Another hypothesis is that prior exposure to chemotherapy including anthracyclines in the neoadjuvant phase (Stratum B) may itself exert anti-tumor immune-activating functions^{29,30}, preparing the ground for subsequent ICI that may further maintain or boost an effective immune response. If so, our findings would not be in contrast with the preclinical observation that neoadjuvant immunotherapy is more efficacious than in the adjuvant setting, considering that this preclinical model lacks the exposure to prior chemotherapy²⁴. Similarly, data in melanoma patients showing a larger effect of immunotherapy when administered neoadjuvantly as compared to adjuvantly, refer to regimens including ICIs alone²⁵.

PD-L1 expression was confirmed in A-BRAVE as prognostic but not predictive for the efficacy of avelumab, consistently with other neoadjuvant immunotherapy trials in TNBC^{10,20}. Intriguingly, there was a signal for improved outcome with avelumab in case of PD-L1 negative disease and apparently no impact in PD-L1 positive patients. To one hand, the overall good outcome of the PD-L1 positive group with low number of events may have prevented the possibility to detect some effect of avelumab. To the other hand these results further suggest a higher plasticity of the tumor immune microenvironment of early TNBC as compared to advanced disease. The IHC 73-10 Research Use Only assay used in A-BRAVE does not have a clinically validated scoring system and no formal comparison to the performance of clinically used assays is available. The main cut-off applied ($\geq 21\%$) was

defined in our previous work to provide optimal prognostic separation, and was not designed to predict immunotherapy benefit¹⁴. For additional clarity, no significant interaction with treatment benefit was observed using different cut-offs or the continuous variable.

In conclusion, adjuvant avelumab versus observation for high-risk TNBC patients, although not improving DFS, may potentially reduce the risk of death. This finding requires confirmation in larger trials before claiming potential impact in clinical practice.

Acknowledgments

The authors would like to thank patients and their families, investigators, co-investigators, and the study teams at all participating centers.

Fundings

This trial was developed and sponsored by the Department of Surgery, Oncology and Gastroenterology of the University of Padova, Italy, and the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945) financially supported the study and supply of avelumab.

Competing Interests Statement

The authors report the following completing interests.

Pierfranco Conte has received research funding to his institution from the healthcare business of Merck KGaA, Darmstadt, Germany; and is listed as co-inventor in patent applications for HER2DX.

Maria Vittoria Dieci declares (outside the submitted work) personal fees for an advisory/consultancy role from Lilly, Novartis, Pfizer, Roche, Seagen, Gilead Sciences, Exact Sciences, Daiichi Sankyo, AstraZeneca and MSD; research grants to her institution from Roche and AstraZeneca; honoraria for a speaker role from Lilly; travel/accommodation support from Roche, Gilead Sciences and Lilly; and is listed as co-inventor in patent applications for HER2DX.

Giancarlo Bisagni declares no conflicts of interests.

Peter Schmid receives honoraria or consultation fees from AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Pfizer, Puma, Roche, Eisai and Celgene; and receives grant/funding to his institution from Astellas, AstraZeneca, Genentech, Novartis, Oncogenex, Roche, Medivation and Merck.

Alberto Zambelli has received fees in advisory boards from Roche, Pfizer, Lilly, Novartis, AstraZeneca, Merck, Gilead, DaiichiSankyo, MenariniStemline, ExactSciences, all outside this work .

Federico Piacentini declares outside the submitted work, the following: consultancy/advisory board for Daichii Sankyo, Novartis, Pfizer, Roche; honoraria as a speaker from Novartis, Lilly, MSD, Pfizer, Roche.

Michelino De Laurentiis has a consulting or advisory role with Roche, Novartis, Pfizer, Lilly, AstraZeneca, MSD, Pierre Fabre, Seagen, Gilead Sciences, Ipsen, and Daiichi Sankyo Europe GmbH; receives speaker bureau fees from Novartis; honoraria from Roche, Novartis, Pfizer, Lilly, Pierre Fabre, AstraZeneca, MSD, Seagen, Gilead Sciences, Ipsen, Exact Sciences, TOMA Biosciences, Daiichi Sankyo Europe GmbH and Veracyte; research funding to his institution from Novartis, Roche, Lilly, Pfizer, Daiichi Sankyo, MSD, BMS, Genzyme and AstraZeneca; and has stock and other ownership interests with Arvinas.

Adolfo G. Favaretto declares no conflicts of interests.

Stefano Tamberi declares no conflicts of interests.

Giulia Valeria Bianchi has an advisory role with Lilly, Daiichi/AstraZeneca, MSD, Gilead Sciences and Novartis.

Claudio Zamagni receives grants/research support from Roche, AstraZeneca, Daiichi Sankyo, Gilead Sciences, MSD, GlaxoSmithKline, Eisai, Pfizer, Lilly, Novartis, Exact Sciences and Menarini Stemline; and receives honoraria or consultation fees from Roche, AstraZeneca, Daiichi Sankyo, Gilead Sciences, MSD, GlaxoSmithKline, Eisai, Pfizer, Lilly, Novartis, Exact Sciences, Menarini Stemline and Istituto Gentili.

Saverio Cinieri declares no conflicts of interests.

Domenico C. Corsi declares no conflicts of interests.

Lucia Del Mastro receives personal grants for advisory/consultancy/speaker activities from Agendia, AstraZeneca, Daiichi Sankyo, Lilly, Eisai, Exact Sciences, Gilead Sciences, GlaxoSmithKline, Ipsen, Roche, Seagen, Menarini Stemline, MSD, Novartis, Olema, Pierre Fabre and Pfizer.

Antonella Ferro received honoraria from Pfizer, Novartis, Daiichi Sankyo, Eli Lilly, Seagen, Gilead, Astra Zeneca; travel support from Ipsen, Novartis; research support (to the Institution) from Pfizer.

Alessandra Gennari receives personal fees for advisory board from: Eisai, Novartis, AstraZeneca, Roche, Gentili, Daiichi-Sankyo, Pfizer, Eli Lilly, menarini Stemline; receives honoraria as invited speaker from Eli Lilly, Exact Sciences, Gilead, Eisai; declares non-financial relationships with Pharmanutra (provision of dietary supplements for trials).

Marta Mion receives honoraria fees for lectures, presentations, speakers bureaus from Novartis, Accord, Istituto Gentili, Seagen, Daiichi Sankyo, Pfizer, AstraZeneca and Genetic; support for attending meetings and/or travel from Takeda, Novartis, Ipsen, Istituto Gentili, Lilly, Gilead Sciences, Seagen, AstraZeneca, Pfizer and Daiichi Sankyo; and is an investigator in a clinical trial with Roche.

Antonino Musolino receives research funding from Lilly, Gilead Sciences, Roche, Pfizer and Seagen; travel grants from Roche, Lilly and Novartis; and attends advisory boards for Lilly, Roche, Gilead Sciences, AstraZeneca and Daiichi Sankyo.

Lorenzo Nicolé declares no conflict of interests.

Paola Del Bianco declares no conflicts of interests.

Gian Luca De Salvo declares no conflicts of interests.

Valentina Guarneri receives personal fees for advisory board membership from AstraZeneca, Daiichi Sankyo, Lilly, Gilead Sciences, MSD, Novartis, Pfizer, Olema Oncology, Pierre Fabre, Roche and Menarini Stemline; as an invited speaker for AstraZeneca, Daiichi Sankyo, Lilly, Exact Sciences, Gilead, GlaxoSmithKline, Novartis, Roche, Zentiva, and Menarini Stemline; and for expert testimony from Lilly; and is listed as co-inventor in patent applications for HER2DX.

Figure Legends/Captions

Fig. 1 CONSORT diagram

Fig. 2 Kaplan–Meier plots for DFS according to treatment arm. (A) Whole intent-to-treat population and (B) Stratum B, both co-primary endpoints. CI, confidence interval; DFS, disease-free survival; HR, hazard ratio.

Fig. 3 Kaplan–Meier plots for OS and DDFS according to treatment arm in the whole intent-to-treat population. (A) OS, secondary endpoint and (B) DDFS, exploratory endpoint. CI, confidence interval; DDFS, distant disease-free survival; HR, hazard ratio; OS, overall survival.

Fig. 4 Subgroup analysis of DFS. CI, confidence interval; DFS, disease-free survival; HR, hazard ratio; VUS, variance of unknown significance.

Fig. 5 Kaplan–Meier plots for DFS according to PD-L1 status. (A) DFS by PD-L1; (B) DFS in patients with PD-L1-negative (<21%) tumor by treatment arm; (C) DFS in patients with PD-L1-positive ($\geq 21\%$) tumor by treatment arm (secondary endpoint).

Declaration of generative AI in scientific writing

During the preparation of this work the author(s) used ChatGpt in order to improve readability and language. After using this tool, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication

References

1. Loibl S, André F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Annals of Oncology*. February 2024;35(2):159–182.
2. Masuda N, Lee S-J, Ohtani S, Im Y-H, Lee E-S, Yokota I, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. *N Engl J Med*. June 1, 2017;376(22):2147–2159.
3. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *The Lancet*. July 2014;384(9938):164–172.
4. Miglietta F, Dieci MV, Griguolo G, Guarneri V. Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer. *Cancer Treat Rev*. July 2021;98:102222.
5. Prowell TM, Beaver JA, Pazdur R. Residual Disease after Neoadjuvant Therapy — Developing Drugs for High-Risk Early Breast Cancer. *New England Journal of Medicine*. February 14, 2019;380(7):612–615.
6. Hernandez-Aya LF, Chavez-MacGregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, et al. Nodal Status and Clinical Outcomes in a Large Cohort of Patients With Triple-Negative Breast Cancer. *Journal of Clinical Oncology*. July 1, 2011;29(19):2628–2634.
7. Luen S, Virassamy B, Savas P, Salgado R, Loi S. The genomic landscape of breast cancer and its interaction with host immunity. *Breast*. October 2016;29:241–250.
8. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. *New England Journal of Medicine*. November 29, 2018;379(22):2108–2121.
9. Cortes J, Rugo HS, Cescon DW, Im S-A, Yusof MM, Gallardo C, et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. *New England Journal of Medicine*. July 21, 2022;387(3):217–226.
10. Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. *New England Journal of Medicine*. February 27, 2020;382(9):810–821.
11. Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau H-T, Forero-Torres A, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. *Breast Cancer Res Treat*. February 23, 2018;167(3):671–686.
12. von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. *New England Journal of Medicine*. February 14, 2019;380(7):617–628.
13. Spiessens B, Debois M. Adjusted significance levels for subgroup analyses in clinical trials. *Contemp Clin Trials*. November 2010;31(6):647–656.

14. Dieci MV, Tsvetkova V, Griguolo G, Miglietta F, Tasca G, Giorgi CA, et al. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I–III patients treated with standard therapy. *Eur J Cancer*. September 2020;136:7–15.
15. Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, et al. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer. *JAMA Oncol*. May 1, 2020;6(5):676.
16. Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. *The Lancet*. October 2020;396(10257):1090–1100.
17. Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer J-U, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. *Annals of Oncology*. August 2019;30(8):1279–1288.
18. Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. *Annals of Oncology*. May 2022;33(5):534–543.
19. Loibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer J-U, et al. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. *Annals of Oncology*. November 2022;33(11):1149–1158.
20. Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. *New England Journal of Medicine*. February 10, 2022;386(6):556–567.
21. Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kümmel S, et al. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. *New England Journal of Medicine*. November 28, 2024;391(21):1981–1991.
22. Ignatiadis M, Bailey A, McArthur H, El-abed S, de Azambuja E, Metzger O, et al. Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer. *JAMA*. April 1, 2025;333(13):1150.
23. Versluis JM, Long G V., Blank CU. Learning from clinical trials of neoadjuvant checkpoint blockade. *Nat Med*. April 9, 2020;26(4):475–484.
24. Liu J, Blake SJ, Yong MCR, Harjunpää H, Ngiow SF, Takeda K, et al. Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. *Cancer Discov*. December 1, 2016;6(12):1382–1399.
25. Patel SP, Othus M, Chen Y, Wright GP, Yost KJ, Hyngstrom JR, et al. Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. *New England Journal of Medicine*. March 2, 2023;388(9):813–823.
26. Blondeaux E, Xie W, Carmisciano L, Mura S, Sanna V, De Laurentiis M, et al. Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the

- 1 Gruppo Italiano Mammella and Mammella Intergruppo trials. *EClinicalMedicine*. April
2 2024;70:102501.
- 3 27. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman J-AW, et al. Proposal for
4 Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP
5 System. *Journal of Clinical Oncology*. May 20, 2007;25(15):2127–2132.
- 6 28. Hofherr M, Hedgecorth J, Ademuyiwa FO, Peterson LL, Bagegni NA, Suresh R, et al. Abstract
7 P3-06-06: Real-world analysis of adverse events of patients with triple negative breast cancer
8 receiving therapy per KEYNOTE-522. *Cancer Res*. March 1, 2023;83(5_Supplement):P3-06-06-
9 P3-06-06.
- 10 29. Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, et al. Prognostic value of
11 tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-
12 negative breast cancer: a retrospective multicenter study. *Annals of Oncology*. March
13 2014;25(3):611–618.
- 14 30. Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, et al.
15 Immune induction strategies in metastatic triple-negative breast cancer to enhance the
16 sensitivity to PD-1 blockade: the TONIC trial. *Nat Med*. June 13, 2019;25(6):920–928.
- 17

Tables


Table 1. Characteristics of patients at baseline

Characteristic		Avelumab (n= 235)	Control (n= 231)
Age,	Median (range)	50.9 (28.3–78.6)	51.9 (28.8–79.9)
ECOG PS, n (%)	0	233 (99.6)	225 (98.3)
	1	1 (0.4)	4 (1.7)
	Unknown	1	2
ER expression, n (%) ^a	ER 0%	218 (92.7)	205 (88.7)
	ER $\geq 1\%$ ^b	14 (4.3)	25 (8.7)
	Unknown	3	1
HER2 status, n (%) ^a	0	162 (69.5)	166 (71.9)
	IHC 1+/2+ (ISH neg)	71 (30.5)	65 (28.1)
	Unknown	2	
gBRCA status, n (%)	Mutated (pathogenic variant)	24 (10.2)	27 (11.7)
	Wild type/VUS	113 (48.1)	113 (48.9)
	Unknown	98 (41.7)	91 (39.4)
Carboplatin received	Yes	82 (35.0%)	59 (25.5%)
Stratum A (adjuvant)		40 (17.8)	43 (18.6)
AJCC stage at surgery, n (%) ^c	II	20 (50.0)	22 (51.2)
	III	20 (50.0)	21 (48.8)
Stratum B (post-neoadjuvant)		195 (83.0)	188 (81.4)
AJCC stage at surgery, n (%) ^d	ypT1 & ypN0	93 (47.7)	85 (45.2)
	\geq ypT2 & ypN0	31 (15.9)	38 (20.2)
	Any ypT & ypN1	49 (25.1)	42 (22.3)
	Any ypT & \geq ypN2	22 (11.3)	23 (12.2)
Adjuvant capecitabine, n (%) ^d		52 (26.7)	38 (20.2)


^aER expression and HER2 status on surgical sample.^bIncluding five cases with ER $\geq 10\%$, three in the avelumab arm and two in the control arm.^cCalculated over the total of patients in Stratum A.^dCalculated over the total of patients in Stratum B.

AJCC, American Joint Committee on Cancer; ECOG PS, Eastern Cooperative Oncology Group performance status; ER, estrogen receptor; gBRCA, germline breast cancer gene; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridization; neg, negative; VUS, variance of unknown significance.


Journal Pre-proof





2A




2B



Journal Pre-proof

3A**3B**

Journal Pre-proof

Disease Free Survival

*test for interaction

